{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:16:28Z","timestamp":1776723388391,"version":"3.51.2"},"reference-count":36,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Combining pathogen reduction technology (PRT) with blood screening may alleviate concerns over the risk of transfusion\u2010transmitted infections (TTI) and support changes in blood donor selection to potentially increase blood availability. This study aimed to estimate the residual risk of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) transfusion\u2010transmission in Canada after implementing PRT, while eliminating deferrals for sexual risk behaviors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study Design and Methods<\/jats:title><jats:p>A probabilistic approach that combined Bayesian networks with Monte Carlo simulations was used to estimate the risk of transfusing HIV\u2010, HBV\u2010, or HCV\u2010contaminated blood components. Different scenarios were considered to compare the current residual risk after PRT implementation, with and without donor deferral criteria for sexual risk behaviors. Donor profiles and blood component outcomes were simulated based on a literature review including the prevalence and incidence of HIV, HBV, and HCV in the Canadian blood donor population; the use of current blood screening assays; and HIV, HBV, and HCV blood donor viral loads.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the universal PRT scenario (i.e., with PRT\/without deferral criteria), the estimated risks of HIV, HBV, and HCV transmission were significantly lower than those in the currently observed scenario (i.e., without PRT\/with deferral criteria).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This risk model suggests that PRT for platelets and plasma (and eventually for RBCs when available) significantly reduces the residual risks of HIV, HBV and HCV transfusion\u2010transmission and could enable the removal of blood donor deferral criteria for sexual risk behaviors.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.17981","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T13:38:01Z","timestamp":1723297081000},"page":"1949-1958","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Implementing pathogen reduction technology while discontinuing blood donor deferral criteria for sexual risk behaviors: A simulation study"],"prefix":"10.1111","volume":"64","author":[{"given":"Marie\u2010Pier","family":"Domingue","sequence":"first","affiliation":[{"name":"Medical Affairs and Innovation, H\u00e9ma\u2010Qu\u00e9bec  Montreal Quebec Canada"},{"name":"Facult\u00e9 des Sciences Universit\u00e9 de Sherbrooke  Sherbrooke Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5332-2789","authenticated-orcid":false,"given":"Sheila F.","family":"O'Brien","sequence":"additional","affiliation":[{"name":"Epidemiology &amp; Surveillance Canadian Blood Services  Ottawa Ontario Canada"},{"name":"School of Epidemiology &amp; Public Health University of Ottawa  Ottawa Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1096-698X","authenticated-orcid":false,"given":"Yves","family":"Gr\u00e9goire","sequence":"additional","affiliation":[{"name":"Medical Affairs and Innovation, H\u00e9ma\u2010Qu\u00e9bec  Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4213-5013","authenticated-orcid":false,"given":"Marion C.","family":"Lanteri","sequence":"additional","affiliation":[{"name":"Creative Testing Solutions  Tempe Arizona USA"},{"name":"Department of Laboratory Medicine University of California San Francisco  San Francisco California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5865-6366","authenticated-orcid":false,"given":"Susan L.","family":"Stramer","sequence":"additional","affiliation":[{"name":"Infectious Disease Consultant  North Potomac Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F\u00e9lix","family":"Camirand Lemyre","sequence":"additional","affiliation":[{"name":"Facult\u00e9 des Sciences Universit\u00e9 de Sherbrooke  Sherbrooke Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1748-4198","authenticated-orcid":false,"given":"Antoine","family":"Lewin","sequence":"additional","affiliation":[{"name":"Medical Affairs and Innovation, H\u00e9ma\u2010Qu\u00e9bec  Montreal Quebec Canada"},{"name":"Facult\u00e9 de M\u00e9decine et des Sciences de la Sant\u00e9 Universit\u00e9 de Sherbrooke  Sherbrooke Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,8,10]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-833996"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16250"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2017.03.010"},{"key":"e_1_2_8_5_1","article-title":"HIV residual risk in Canada for apheresis source plasma donation without deferral for men who have sex with men","volume":"1","author":"Aub\u00e9 E","year":"2021","journal-title":"Vox Sang"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.04215.x"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.13277"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12826"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tracli.2022.06.001"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12867"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2009.02322.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-1992-2"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0042-9007.2004.00406.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14050"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00201-1"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00029"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16543"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15057"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15807"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16165"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17878"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15098"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16950"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8248811"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02635.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15103"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15420"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200309050-00005"},{"key":"e_1_2_8_29_1","unstructured":"Abbott Laboratories.ABBOTT PRISM Hepatitis B Virus Core Antigen \u2013 Package Insert [Internet].2014. Available from:https:\/\/www.fda.gov\/media\/72155\/download"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6532(06)80005-3"},{"key":"e_1_2_8_31_1","unstructured":"Grifols Diagnostic Solutions Inc.Procleix\u00ae Ultrio Plus\u00ae Assay \u2013 Package Insert [Internet].2020. Available from:https:\/\/www.fda.gov\/media\/73892\/download"},{"key":"e_1_2_8_32_1","unstructured":"Abbott Laboratories.ABBOTT PRISM Human Immunodeficiency Virus Types 1 and 2 \u2013 Package Insert [Internet].2014. Available from:https:\/\/www.fda.gov\/media\/77612\/download"},{"key":"e_1_2_8_33_1","unstructured":"Abbott Laboratories.ABBOTT PRISM Hepatitis C Virus Encoded Antigens \u2013 Package Insert [Internet].2019. Available from:https:\/\/www.fda.gov\/media\/73334\/download"},{"key":"e_1_2_8_34_1","unstructured":"Abbott Laboratories.ABBOTT PRISM Antibody to Hepatitis B Surface Antigen \u2013 Package Insert [Internet].2019. Available from:https:\/\/www.fda.gov\/media\/149417\/download"},{"key":"e_1_2_8_35_1","unstructured":"Cerus Corporation.INTERCEPT Blood SystemTMfor Plasma \u2013 Package Insert [Internet].2016. Available from:https:\/\/intercept-canada.com\/wp-content\/uploads\/sites\/3\/2021\/02\/INTERCEPT-CANADA-PACKAGE_INSERT-PLASMA_21may16.pdf"},{"key":"e_1_2_8_36_1","unstructured":"Cerus Corporation.INTERCEPT\u00ae Blood System for Platelets \u2013 Package Insert [Internet].2022. Available from:https:\/\/intercept-canada.com\/wp-content\/uploads\/sites\/3\/2022\/11\/SPC-00400-AW-v3.0.pdf"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/voxs.12524"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.17981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T04:32:31Z","timestamp":1729485151000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.17981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1111\/trf.17981"],"URL":"https:\/\/doi.org\/10.1111\/trf.17981","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,10]]},"assertion":[{"value":"2024-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}